Swarna Jayasinghe, MD
Cardiovascular Disease · Galloway, NJNPI 1437176237
Payments from drug & device makers
Across 256 payments — averaging $19.65 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novartis$696
- ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$593
- Johnson & Johnson$462
- E.r. Squibb & Sons, L.L.C.$399
- AbbVie$249
- Alnylam Pharmaceuticals Inc.$244
- plus $2K from 30 others
What the payments were for
- Food & beverage$5,032100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novartis | 59 | $696 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 27 | $593 |
| Johnson & Johnson | 38 | $462 |
| E.r. Squibb & Sons, L.L.C. | 30 | $399 |
| AbbVie | 2 | $249 |
| Alnylam Pharmaceuticals Inc. | 2 | $244 |
| Boston Scientific | 23 | $201 |
| Amgen | 10 | $158 |
| Boehringer Ingelheim | 3 | $149 |
| Novo Nordisk | 4 | $149 |
| Bridgebio Pharma, Inc. | 1 | $135 |
| Viiv Healthcare Company | 1 | $124 |
| Teva Pharmaceuticals USA, Inc. | 1 | $123 |
| Pfizer | 8 | $123 |
| Gilead | 1 | $120 |
| Acadia Pharmaceuticals Inc | 2 | $119 |
| Insmed, Inc. | 1 | $119 |
| Cardiovascular Systems Inc. | 1 | $111 |
| Neurocrine Biosciences, Inc. | 1 | $103 |
| Merck | 7 | $98 |
| Esperion Therapeutics, Inc. | 5 | $75 |
| AstraZeneca | 5 | $67 |
| Penumbra, Inc. | 1 | $57 |
| Bayer | 3 | $49 |
| Amarin Pharma, Inc. | 3 | $44 |
| Kiniksa Pharmaceuticals, Ltd. | 3 | $42 |
| Regeneron Healthcare Solutions, Inc. | 2 | $33 |
| Daiichi Sankyo Inc. | 2 | $33 |
| Lexicon Pharmaceuticals, Inc. | 2 | $30 |
| Preventice Services, LLC | 2 | $26 |
| Sanofi | 1 | $18 |
| Sage Therapeutics, LLC | 1 | $18 |
| Harmony Biosciences LLC | 1 | $17 |
| Sanofi-aventis U.S. LLC | 1 | $17 |
| Chiesi USA, Inc. | 1 | $16 |
| Kiniksa Pharmaceuticals International, PLC | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$5,032 in reported general payments places this provider in the 65th percentile of 1,006 cardiovascular disease providers in New Jersey.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 414 | $559,485 |
| EntrestoSacubitril/Valsartan | 172 | $174,782 |
| XareltoRivaroxaban | 86 | $104,553 |
| FarxigaDapagliflozin Propanediol | 89 | $94,841 |
| JardianceEmpagliflozin | 79 | $73,597 |
| MultaqDronedarone Hcl | 16 | $23,832 |
| Metoprolol Succinate | 855 | $15,686 |
| Valsartan | 289 | $14,953 |
| Icosapent Ethyl | 23 | $12,872 |
| Rosuvastatin Calcium | 785 | $12,439 |
| Atorvastatin Calcium | 1,053 | $12,251 |
| CrestorRosuvastatin Calcium | 20 | $11,087 |
| Ezetimibe | 411 | $10,848 |
| VascepaIcosapent Ethyl | 16 | $9,841 |
| Nebivolol Hcl | 118 | $9,586 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $123 | $559,485414 claims |
| NovartisEntresto | $696 | $174,782172 claims |
| AstraZenecaFarxiga, Crestor | $67 | $105,928109 claims |
| Johnson & JohnsonXarelto | $462 | $104,55386 claims |
| Boehringer IngelheimJardiance | $149 | $73,59779 claims |
| Sanofi-aventis U.S. LLCMultaq, Plavix | $17 | $26,74128 claims |
| Esperion Therapeutics, Inc.Nexletol | $75 | $7,29113 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 1,006 cardiovascular disease providers in New Jersey.
Other cardiovascular disease in Galloway
- Haitham DibGalloway$173K
- Robert KippermanMorristown$5.3M
- Sharan MahalBridgewater$3.5M
- Linda GillamMorristown$2.2M
- Mark GelerntHaddon Heights$2M
- Robert FishbergSpringfield$1.9M
- Dilip ViswanathHaddon Heights$1.8M
- Marc CohenNewark$1M
- Jasjit WaliaElizabeth$859K
- Sajjad SabirCamden$742K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.